

Answering Reviewers

July 31, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 12268-review.docx).

Title: Nucleos(t)ide Analogues for Hepatitis B Virus-Related Hepatocellular Carcinoma After Radical Resection

Author: Yang Ke, Lin Wang, Le-Qun Li, Jian-Hong Zhong

Name of Journal: *World Journal of Hepatology*

ESPS Manuscript NO: 12268

The manuscript has been improved according to the suggestions of reviewers:
1 Format has been updated.

2 Revision has been made according to the suggestions of the reviewer.

- (1) I have carefully read references which you mentioned and added them to our article. It is a great honor for us to quote Professor Hann's papers.
- (2) I have noticed that of the 19 included studies, besides patients who underwent surgical resection (6505, 96.6%), NA therapy has been also applied for patients who underwent ablative procedures as follows: RFA (176, 2.6%), PEI (7, 0.1%) and even TACE (49, 0.7%). I have described these data in the section of "POSTOPERATIVE NA THERAPY AND RECURRENCE-FREE SURVIVAL" and Table 1, and included those with ablative procedures in conclusion.
- (3) Thank you for bringing these important guidelines to my attention, and I will carefully delineate these various criteria in the section of

"INDICATIONS AND DURATION OF NA THERAPY AFTER HCC SURGERY".

- (4) These statement came from Asian-Pacific consensus statement on the management of chornic hepatitis B: a 2012 update (Hepatol Int 2012; 6: 554).
- (5) Since NA therapy cannot completely eradicate HBV, some investigators have advocated lifelong treatment, especially given the high mortality of HBV-related HCC. Although there is not sufficient evidence nowadays, I think it is very important to put forward this opinion, because it is an active treatment that may improve patients' prognosis.

3 I have added the latest articles on outcomes of NA therapy in patients with HBV-related HCC. References and typesetting were corrected.

Thank you for publishing our manuscript in the World Journal of Hepatology.

Sincerely yours,


Jian-Hong Zhong, MD, PhD

Department of Hepatobiliary Surgery

Affiliated Tumor Hospital of Guangxi Medical University

He Di Rd. #71, Nanning 530021, P.R. China

Email: zhongjianhong66@163.com

Phone: +86-771-5330855

Fax: +86-771-5312000